CA1143640A - Process for manufacture of pyruvate oxidase and its use for the analysis and kit - Google Patents
Process for manufacture of pyruvate oxidase and its use for the analysis and kitInfo
- Publication number
- CA1143640A CA1143640A CA000324045A CA324045A CA1143640A CA 1143640 A CA1143640 A CA 1143640A CA 000324045 A CA000324045 A CA 000324045A CA 324045 A CA324045 A CA 324045A CA 1143640 A CA1143640 A CA 1143640A
- Authority
- CA
- Canada
- Prior art keywords
- pyruvate
- pyruvate oxidase
- hydrogen peroxide
- oxidase
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108010042687 Pyruvate Oxidase Proteins 0.000 title claims abstract description 61
- 238000004458 analytical method Methods 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 22
- 230000008569 process Effects 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims abstract description 53
- 229940107700 pyruvic acid Drugs 0.000 claims abstract description 26
- 238000006243 chemical reaction Methods 0.000 claims abstract description 22
- 241000192001 Pediococcus Species 0.000 claims abstract description 11
- 241000194017 Streptococcus Species 0.000 claims abstract description 10
- 244000005700 microbiome Species 0.000 claims abstract description 8
- 241000193798 Aerococcus Species 0.000 claims abstract description 6
- 238000012258 culturing Methods 0.000 claims abstract description 6
- 239000001963 growth medium Substances 0.000 claims abstract description 3
- 235000015097 nutrients Nutrition 0.000 claims abstract description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 55
- 102000004190 Enzymes Human genes 0.000 claims description 37
- 108090000790 Enzymes Proteins 0.000 claims description 37
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 25
- 229940076788 pyruvate Drugs 0.000 claims description 23
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims description 21
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 19
- 239000001301 oxygen Substances 0.000 claims description 19
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- VWWQXMAJTJZDQX-UHFFFAOYSA-N Flavine adenine dinucleotide Natural products C1=NC2=C(N)N=CN=C2N1C(C(O)C1O)OC1COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UHFFFAOYSA-N 0.000 claims description 17
- 229960002363 thiamine pyrophosphate Drugs 0.000 claims description 14
- 235000008170 thiamine pyrophosphate Nutrition 0.000 claims description 14
- 239000011678 thiamine pyrophosphate Substances 0.000 claims description 14
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 claims description 14
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 claims description 13
- 229910019142 PO4 Inorganic materials 0.000 claims description 11
- 102000003992 Peroxidases Human genes 0.000 claims description 11
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 10
- 239000010452 phosphate Substances 0.000 claims description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 10
- 241000193792 Aerococcus viridans Species 0.000 claims description 9
- 238000006911 enzymatic reaction Methods 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 241000604136 Pediococcus sp. Species 0.000 claims description 7
- 241000194022 Streptococcus sp. Species 0.000 claims description 6
- LIPOUNRJVLNBCD-UHFFFAOYSA-N acetyl dihydrogen phosphate Chemical compound CC(=O)OP(O)(O)=O LIPOUNRJVLNBCD-UHFFFAOYSA-N 0.000 claims description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 6
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 claims description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000001569 carbon dioxide Substances 0.000 claims description 5
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 claims description 5
- 229910052816 inorganic phosphate Inorganic materials 0.000 claims description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 4
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 4
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims description 4
- 229910001424 calcium ion Inorganic materials 0.000 claims description 4
- 229910001429 cobalt ion Inorganic materials 0.000 claims description 4
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 claims description 4
- 210000004748 cultured cell Anatomy 0.000 claims description 4
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 4
- 229910001437 manganese ion Inorganic materials 0.000 claims description 4
- PLIKAWJENQZMHA-UHFFFAOYSA-N p-hydroxyphenylamine Natural products NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 claims 1
- 150000004728 pyruvic acid derivatives Chemical class 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 5
- 229940088598 enzyme Drugs 0.000 description 35
- 238000003556 assay Methods 0.000 description 33
- 239000003153 chemical reaction reagent Substances 0.000 description 33
- 230000000694 effects Effects 0.000 description 32
- 239000000243 solution Substances 0.000 description 31
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 27
- 229960002163 hydrogen peroxide Drugs 0.000 description 19
- 239000008363 phosphate buffer Substances 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 13
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 10
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 10
- 102000013009 Pyruvate Kinase Human genes 0.000 description 10
- 108020005115 Pyruvate Kinase Proteins 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 229960001484 edetic acid Drugs 0.000 description 9
- 235000021317 phosphate Nutrition 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 8
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 8
- 239000000523 sample Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 102000004316 Oxidoreductases Human genes 0.000 description 6
- 108090000854 Oxidoreductases Proteins 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000036284 oxygen consumption Effects 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 5
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 5
- 239000007979 citrate buffer Substances 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 102000002281 Adenylate kinase Human genes 0.000 description 3
- 108020000543 Adenylate kinase Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 238000007398 colorimetric assay Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- JKVUQLWTIZFTMF-UHFFFAOYSA-M potassium;2-oxopropanoate Chemical compound [K+].CC(=O)C([O-])=O JKVUQLWTIZFTMF-UHFFFAOYSA-M 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 108010017192 4-hydroxy-4-methyl-2-oxoglutarate aldolase Proteins 0.000 description 2
- 102000003736 ATP Synthetase Complexes Human genes 0.000 description 2
- 108010082072 ATP Synthetase Complexes Proteins 0.000 description 2
- ROWKJAVDOGWPAT-UHFFFAOYSA-N Acetoin Chemical compound CC(O)C(C)=O ROWKJAVDOGWPAT-UHFFFAOYSA-N 0.000 description 2
- 102100029589 Acylpyruvase FAHD1, mitochondrial Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical class [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000017055 Lipoprotein Lipase Human genes 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 108010069823 Oxaloacetate decarboxylase Proteins 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 238000005377 adsorption chromatography Methods 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- XTDYIOOONNVFMA-UHFFFAOYSA-N dimethyl pentanedioate Chemical compound COC(=O)CCCC(=O)OC XTDYIOOONNVFMA-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000003269 fluorescent indicator Substances 0.000 description 2
- 238000007421 fluorometric assay Methods 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Chemical class 0.000 description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HOLHYSJJBXSLMV-UHFFFAOYSA-N 2,6-dichlorophenol Chemical compound OC1=C(Cl)C=CC=C1Cl HOLHYSJJBXSLMV-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 108010066906 Creatininase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- 101100080807 Drosophila melanogaster mt:ND2 gene Proteins 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- IWNWLPUNKAYUAW-UHFFFAOYSA-N Ethylendiamine dihydroiodide Chemical compound I.I.NCCN IWNWLPUNKAYUAW-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000057621 Glycerol kinases Human genes 0.000 description 1
- 108700016170 Glycerol kinases Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 101150016680 MT-ND2 gene Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical class [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100028488 NADH-ubiquinone oxidoreductase chain 2 Human genes 0.000 description 1
- 101150102231 ND2 gene Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SRBFZHDQGSBBOR-KLVWXMOXSA-N beta-L-arabinopyranose Chemical compound O[C@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KLVWXMOXSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000011575 calcium Chemical class 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 1
- 239000000727 fraction Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- GFAZHVHNLUBROE-UHFFFAOYSA-N hydroxymethyl propionaldehyde Natural products CCC(=O)CO GFAZHVHNLUBROE-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- RSAZYXZUJROYKR-UHFFFAOYSA-N indophenol Chemical compound C1=CC(O)=CC=C1N=C1C=CC(=O)C=C1 RSAZYXZUJROYKR-UHFFFAOYSA-N 0.000 description 1
- 108010047235 indophenol oxidase Proteins 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 235000002908 manganese Nutrition 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000001455 metallic ions Chemical class 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000006395 oxidase reaction Methods 0.000 description 1
- 229960003903 oxygen Drugs 0.000 description 1
- -1 phospho-kinase Proteins 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000011591 potassium Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 150000003609 titanium compounds Chemical class 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- ORZHVTYKPFFVMG-UHFFFAOYSA-N xylenol orange Chemical compound OC(=O)CN(CC(O)=O)CC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(CN(CC(O)=O)CC(O)=O)C(O)=C(C)C=2)=C1 ORZHVTYKPFFVMG-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Chemical class 0.000 description 1
- 229910052725 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/03—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with oxygen as acceptor (1.2.3)
- C12Y102/03003—Pyruvate oxidase (1.2.3.3)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/885—Streptococcus
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
Pyruvate oxidase is produced by a process which comprises culturing A pyruvate oxidase-producing microorganism belonging to the genus Pediococcus, Streptococcus or Aerococcus in a nutrient culture medium, and isolating the pyruvate oxidase thus produced from the culture. also provided by the invention disclosed herein is an analytical method for pyruvic acid in a sample containing pyruvic acid or a system which liberates this acid, which comprises treating said sample with a reaction system containing pyruvate oxidase, and measuring the consumed component or generated component.
Pyruvate oxidase is produced by a process which comprises culturing A pyruvate oxidase-producing microorganism belonging to the genus Pediococcus, Streptococcus or Aerococcus in a nutrient culture medium, and isolating the pyruvate oxidase thus produced from the culture. also provided by the invention disclosed herein is an analytical method for pyruvic acid in a sample containing pyruvic acid or a system which liberates this acid, which comprises treating said sample with a reaction system containing pyruvate oxidase, and measuring the consumed component or generated component.
Description
3~4(~
This in~ention relates to a process for manufacture of pyruvate oxidase and its use in the analysis~ and to a kit for analysis.
Pyruvate oxidase is a hitherto known enzyme which catalyzes the reaction from pyruvic acid, phosphate and oxygen to ~orm acetylphosphate, carbon dioxide and hydrogen peroxide and is derived from a strain of Lactobacillus derbr~ckii.
We have found that the enzyme pyruvate oxidase was produced by bacterial strains B-0667 belonging to the genus Pediococcus and B-0668 belonging to the genus Streptococcus iso-, . , lated from a soil sample collected in a radish field in Ohito-cho, Tagata-gun, Shizuoka~ken, Japan, and that the pyruvate oxidase produced therefrom could be used for pyruvic acid analysis in a sample containing pyruvic acid or various systems which liberate pyruvic acid. We have also found that this enzyme can be used for quantitative analysis of pyruvic acid, measurement of the enzyme activity of enzyme reaction systems which form pyruvate, and quantitative determination of the enzyme and the substrates thereof. Pyruvic acid can be analysed by reacting a sample con-taining pyruvic acid with a reaction system comprising at leastpyruvate oxidase flavine adenine dinucleotide (hereinafter called as FAD), thiamine pyrophosphate, oxygen and phosphate, and we have established an excellent kit for pyruvate analysis and an analytical method for pyruvic acid.
Further we have found that adding a salt which liberates calcium ion, cobalt ion, magnesium ion or manganese ion to the said reaction system results in improvement of the analysis.
Addition of a chromogen or a fluorescent indicator to the reac-tion system provides a convenient and excellent analytical kit and method. Also we have completed a process for manufacture of an enzyme pyruvate oxidase.
~3~
An object of the present invention is to proYide a kit for analysis, especially for diagnostic analysis~ comprising a reaction system containing pyruvate oxidase.
Another object of the present invention is to provide an analytical method for pyruvic acid in a sample containing py-ruvic acid or a pyruvic acid liberating system, which method com-prises treatinq a sample with a reaction system containing pyru-vate oxidase and measuring the consumed component or generated component.
A further object of the present invention is to pro-vide a process for the manufacture of pyruvate oxidase which comprises culturing a pyruvate oxidase-producing microorganism belonging to the genus Pediococcus, Streptococcus or Aerococcus in a nutrient culture medium and isolating the pyruvate oxidase thus produced from the cultured cells thereof.
Other objects, features and advantages of the present invention will become apparent from a consideration of the following description, taken in connection with the accompanying drawings, which are graphs illustrating the present invention, and in which more particularly:
Figure 1 is a graph illustrating the optimum pH of pyruvate oxidase.
Figure 2 is a graph illustrating the heat stability of pyruvate oxidase.
Figure 3 is a graph illustrating the pH-stability of pyruva*e oxidase.
Figure 4 is a graph showing the result of analysis of pyruvic acid by an oxygen electrode using pyruvate oxidase.
Figure 5 is a graph showing the result of analysis of serum by an oxygen electrode using pyruvate oxidase.
Figure 6 is a graph showing the result of analysis of pyruvic acid by a colorimetric method using pyruvate oxidase.
This in~ention relates to a process for manufacture of pyruvate oxidase and its use in the analysis~ and to a kit for analysis.
Pyruvate oxidase is a hitherto known enzyme which catalyzes the reaction from pyruvic acid, phosphate and oxygen to ~orm acetylphosphate, carbon dioxide and hydrogen peroxide and is derived from a strain of Lactobacillus derbr~ckii.
We have found that the enzyme pyruvate oxidase was produced by bacterial strains B-0667 belonging to the genus Pediococcus and B-0668 belonging to the genus Streptococcus iso-, . , lated from a soil sample collected in a radish field in Ohito-cho, Tagata-gun, Shizuoka~ken, Japan, and that the pyruvate oxidase produced therefrom could be used for pyruvic acid analysis in a sample containing pyruvic acid or various systems which liberate pyruvic acid. We have also found that this enzyme can be used for quantitative analysis of pyruvic acid, measurement of the enzyme activity of enzyme reaction systems which form pyruvate, and quantitative determination of the enzyme and the substrates thereof. Pyruvic acid can be analysed by reacting a sample con-taining pyruvic acid with a reaction system comprising at leastpyruvate oxidase flavine adenine dinucleotide (hereinafter called as FAD), thiamine pyrophosphate, oxygen and phosphate, and we have established an excellent kit for pyruvate analysis and an analytical method for pyruvic acid.
Further we have found that adding a salt which liberates calcium ion, cobalt ion, magnesium ion or manganese ion to the said reaction system results in improvement of the analysis.
Addition of a chromogen or a fluorescent indicator to the reac-tion system provides a convenient and excellent analytical kit and method. Also we have completed a process for manufacture of an enzyme pyruvate oxidase.
~3~
An object of the present invention is to proYide a kit for analysis, especially for diagnostic analysis~ comprising a reaction system containing pyruvate oxidase.
Another object of the present invention is to provide an analytical method for pyruvic acid in a sample containing py-ruvic acid or a pyruvic acid liberating system, which method com-prises treatinq a sample with a reaction system containing pyru-vate oxidase and measuring the consumed component or generated component.
A further object of the present invention is to pro-vide a process for the manufacture of pyruvate oxidase which comprises culturing a pyruvate oxidase-producing microorganism belonging to the genus Pediococcus, Streptococcus or Aerococcus in a nutrient culture medium and isolating the pyruvate oxidase thus produced from the cultured cells thereof.
Other objects, features and advantages of the present invention will become apparent from a consideration of the following description, taken in connection with the accompanying drawings, which are graphs illustrating the present invention, and in which more particularly:
Figure 1 is a graph illustrating the optimum pH of pyruvate oxidase.
Figure 2 is a graph illustrating the heat stability of pyruvate oxidase.
Figure 3 is a graph illustrating the pH-stability of pyruva*e oxidase.
Figure 4 is a graph showing the result of analysis of pyruvic acid by an oxygen electrode using pyruvate oxidase.
Figure 5 is a graph showing the result of analysis of serum by an oxygen electrode using pyruvate oxidase.
Figure 6 is a graph showing the result of analysis of pyruvic acid by a colorimetric method using pyruvate oxidase.
2 -~36~0 Figure 7 is a graph showin~ the xesult of ~uantitativeanalysis of serum pyruvic acid using pyruvate oxidase.
Figure 8 is a graph showing the result of analysis of ADP using pyruVate oxidase.
Figure 9 is a graph illustxating the result of analysis of glycerol~ triglyceri:de and serum triglyceride using pyruvate oxidase.
Figure 10 is a graph illustrating the result of analysis of GPT- and GOT-activity using pyruvate oxidase.
Figure 11 (located in the sixth sheet of drawings, with Figure 7) is a correlation diagram of the analysis o~ GPT-activity using pyruvate oxidase.
Figure 12 (located in the seventh sheet of drawings, with Figure 8~ is a correlation diagram of the analysis of GOT-activity using pyruvate oxidase.
The enzyme pyruvate oxidase in this invention catalyzes an oxidative reaction from pyruvic acid, inorganic phosphate and oxygen to form acetyl phosphate, carbon dioxide and hydrogen peroxide, and is preferably manufactured by culturing a pyruvate 20 oxidase-producing microbial strain belonging to the genus Pediococcus, Streptococcus or Aerococcus, for example Pediococcus sp. B-0667, Streptococcus sp. B-0668, Aerococcus viridans IFO
12219 or IFO 12317.
The isolated strain B-0667 and B-0668 hereinabove have the following taxonomical properties.
~ ~ 3 -~3~
_ ~ ~ ' o ~ o . R ~ v 0 3 ,~ _~ O
. ~ D ~ .~
S v ~ v E~ ~ ~
0 t,~ rC
Figure 8 is a graph showing the result of analysis of ADP using pyruVate oxidase.
Figure 9 is a graph illustxating the result of analysis of glycerol~ triglyceri:de and serum triglyceride using pyruvate oxidase.
Figure 10 is a graph illustrating the result of analysis of GPT- and GOT-activity using pyruvate oxidase.
Figure 11 (located in the sixth sheet of drawings, with Figure 7) is a correlation diagram of the analysis o~ GPT-activity using pyruvate oxidase.
Figure 12 (located in the seventh sheet of drawings, with Figure 8~ is a correlation diagram of the analysis of GOT-activity using pyruvate oxidase.
The enzyme pyruvate oxidase in this invention catalyzes an oxidative reaction from pyruvic acid, inorganic phosphate and oxygen to form acetyl phosphate, carbon dioxide and hydrogen peroxide, and is preferably manufactured by culturing a pyruvate 20 oxidase-producing microbial strain belonging to the genus Pediococcus, Streptococcus or Aerococcus, for example Pediococcus sp. B-0667, Streptococcus sp. B-0668, Aerococcus viridans IFO
12219 or IFO 12317.
The isolated strain B-0667 and B-0668 hereinabove have the following taxonomical properties.
~ ~ 3 -~3~
_ ~ ~ ' o ~ o . R ~ v 0 3 ,~ _~ O
. ~ D ~ .~
S v ~ v E~ ~ ~
0 t,~ rC
3 C4 3 ~ 8 ~ c c b ~ ~ , o ~
o R 8 ~ ~ ~
v e v ~ v v ~ o o~ ~ 3 ~ 3 t) u) ~ , ~; ~ ~ ~ a ~ 0 ~ ~ ~ 0 ~ C
O ~ ~ X ~ O o ~ U
O 3 3 C ~~ ~ ~
C .. ..
,0 ~C ~ _ ~3 R n~
O ~ -æ &
~3 ~3~0 B. Microscopic observation:
_ Strain B-0667 Strain B-0668 Shape: spherical, ovoid, pairs, spherical, ovoid, pairs, tetra-shaped or short tetra-shaped or short chain. chain.
Size: 0.5 - 1.0 x 0.5 - 1.0 ~ 0.8 - 1.0 x 1.0 - 1.2 Motility: _ _ Spore: _ _ Gram's stain: + +
Acid-fa8t stain: .. .
C. Physiological properties:
_ ........................ , ~ Strain B-0667 Strain B-0668 .. .
Growth temperature: 45C _ 37C + +
30~C ~ +
; 26~C + +
. 10C + +
5C i or (~) + or ~+) Halotolerance: NaCl 10~ + ~
5.0~ + ~
1.0% ~ +
0% + _ OF-test: fermentative fermentative:
Behavior in oxygen: facultative anaerobic facultative anaerobic Nitrate reduction: _ _ Indole formation: _ _ Hydrogen sulfate formation: _ _ i Gelatin hydrolysis:
~'1~''~
,~
~3~
Table continued:
St:rch hydrolysis:
Esculin hydrolysis: +
Acetoin formation: _ MR-test: _ Catalase: _ O~idase: _ Urease (SSR): _ Urease (Christensen): _ Utilization of citric acid (Christensen): _ Acid ormation from sugar:
adonitol: _ L(+)-arabinose: _ cellobiose: +
dulcitol: _ meso-erythritol: _ fructose: +
fucose: _ galactose:
glucose: +
glycerol: _ inositol: _ inulin: _ lactose: +
raltose: +
mannitol: +
mannose: +
melezitose: _ melibiose: _ "7'`
-~ ~ 6 -~3~;~0 _ . . ..
raffinose: _ L(+~-rhamnose: _ salicin: ~) _ L-sorbose: _ _ sorbitol: _ _ starch: _ sucrose: ~
trehalose: + +
xylose: _ _ ¦ tolerance at 60C for 30 min. _ i ~
.
Consulting "Bergey's Manual of Determinative Bacteriol-ogy, 8th Ed., 1974" and "Cowan, S. T. and Steel, K. J., Manual for the Identification of Medical Bacteria, Cambridge Press, 1974", the strains B-0667 and B-0668 having the taxonomical properties hereinabove, especially Gram positive cocci, catalaseand oxidase negative, fermentative a~id formation from glucose, and no gas formation from sugar (glucose), are referred to as belonging to the genus Pediococcus and the genus Streptococcus.
Comparison of these strains with the identification manual of the above references is as follows.
In the table:~ _ positive more than 85%.
- ~ negative more than 85%.
d ~ varies among ~trains or species.
~_ _ _ . .
. strain B-0667 strain B-0668 genus genu~
. ._ _ ~ _ .__. _ . Pediococcus StreDtococcus growth at 45DC _ _ + d tolerance at 60C
for 30 min. _ ~ _ d glycerol 30tacid formation' _ _ _ d arabinose .
(acid formation) _ _ + d halotolerance _ ~NaCl 10~ _ +
. ~............................... ............... ........ .............. ... .... -. .,~
~3~
Hence the strain B-0667 will be referred to as the genus Pedlococcus or Streptococcus. Consulting the above 'IManual for the Identification of Medical Bacteria" and "J. Gen.Microbiol 26, 185-197 (1961)", the taxonomic properties of the strain B-0667 were almost identical with those of Pediococcus urina-equi, how-ever the characteristics described in "Bergey's Manual of Deter-minative Bacteriology, 8th Ed., 1974" were slightly different therefrom. Therefore the strain B-0667 is referred to as the genus Pedioco;ccus and designated as Pediococcus sp. B-0667 The strain B-0668 resembles the genus Streptococcus rather than the genus Pediococcus. Further consulting the "Manual for the Identification of Medical Bacteria", the strain B-0668 resembles Streptococcus faecium var. durans, however, no taxo-_ _ nomic properties were described in the l'Bergey's Manual" and thereby it is impossible to make a detailed comparison. The strain B-0668, therefore, is referred to as Streptococcus sp.
B-0668.
The strains B-0667 and B-0668 were deposited for perma-nent collection in the Institute for Microbial Industry and Technology, Agency of Industrial Science and Technology, M. I. T.
I., Japan, as deposition numbers FERM-P No. 4438 and FERM-P No.
4439, respectively.
In an embodiment of the present invention, the above Pediococcus sp. B-0667, Streptococcus sp. B-0668, Aerococcus viridans IFO-12219 or Aerococcus viridans IFO-12317 are cultured in a conventional medium for enzyme production. Cultivation can be made by conventional liquid culture and submerged aeration culture is preferable for industrial production.
A conventional medium for microorganisms is preferably used. As for the carbon sources, assimilable carbon sources such as glucose, sucrose, lactose, maltose, fructose, molasses, py-ruvic acid or the like are preferably used. Assimilable nitrogen 3~
sources such as peptone, meat extract, yeast extract, casein hydxolysate or the like can be used. Various inorganic salts such as phosphates~ carbonates, sulfates, or salts of magnesium, calcium, potassium, iron, manganese or zinc can be used.
The culturing temperature can be selected within the range for growth of microbial cells and production of pyruvate oxidase, and is preferably from 2S-37C. The culturing time can be altered depending on conditions and is terminated when the pyruvate oxidase production is substantially complete, and usually ranges from 18-48 hours.
Pyruvate oxidase exists in the cells of microorganisms.
To separate pyruvate oxidase from cultured cells, the cultured mass is filtered or centrifuged to collect the cells, and disrupted by treatment with mechanical means or an enzymatic pro-cess such as lysozyme. Further if necessary pyruvate oxidase is solubilized by adding ethylene-diaminetetraacetic acid (EDTA) and a surfactant such as "Triton X-100" (trade mark) or "Adecatol SO-120" (trade mark) to separate the enzyme. The thus-obtained solution of pyruvate oxidase is treated with or without concen-tration, and thereafter the enzyme is precipitated by salting outwith addition of a soluble salt such as ammonium sulfate or sodium chloride. Low molecular weight impurities are removed by dialysis.
Furthermore impurities in the solution of pyruvate oxidase are preferably removed by adsorption chromatography, ion-exchange chromatography or gel-filtration. The enzyme solution thus ob-tained is treated by vacuum concentration and lyophilization to produce powdered pyruvate oxidase. Further purification can be achieved by conventional purification methods for proteins and enzymes such as adsorption chromatography, ion-exchange chroma-tography or gel~filtration.
Pyruvate oxidase produced by the present invention hasthe following physico-chemical properties, in which abbreviations are used as follows.
_ g _ Pediococcus sp. B-0667; abbreviated as B-0667 ____ .
Streptococcus sp. B~0668; abbreviated as B-0668 .
Aerococcus viridans IFO-12219: abbreviated as IFO-12219 _ . .. ..
Aerococcus viridans IFO-12317: abbreviated as IFO-12317 (1) Enzyme action:
The enzyme catalyzes oxida-tive reaction from pyruvic acid, inorganic phosphate and oxygen to form acetylphosphate, carbon dioxide and hydrogen peroxide.
CH3COCOOH ~ HOPO3 + 02-~CH3COOP03 + C02 + H202 (2) Optimum pH:
The effect of pH on pyruvate oxidase activity is measured. Phosphate buffer solutions of pH 6~8 are used for the assay. The results are shown in Fig. 1 in which the optimum pH
is as follows:
B-0667: pH 6.3-7.5 B-0668: pH 7.5-8.5 IFO-12219: pH 7.0-8.0 IFO-12317: pH 6.8~7.5 Slight variations are observed in phosphate concentra-tion and in the kind of metallic ion.
(3) Heat stability:
Heat stability of the enzyme is determined by incuba-ting in 10 mM phosphate buffer (pH 6.5) containing 10 ~M FAD at 0, 40, 50, 60 and 70C for 10 minutes according to the method of enzyme assay. As shown in Fig. 2 the enzymes obtained from B~0667, IFO-12219 and IFO-12317 are slightly activated at 40 C
and denatured over 60C. The enzyme obtained from B-0668 is not activated at 40C and almost denatured over 60C.
o R 8 ~ ~ ~
v e v ~ v v ~ o o~ ~ 3 ~ 3 t) u) ~ , ~; ~ ~ ~ a ~ 0 ~ ~ ~ 0 ~ C
O ~ ~ X ~ O o ~ U
O 3 3 C ~~ ~ ~
C .. ..
,0 ~C ~ _ ~3 R n~
O ~ -æ &
~3 ~3~0 B. Microscopic observation:
_ Strain B-0667 Strain B-0668 Shape: spherical, ovoid, pairs, spherical, ovoid, pairs, tetra-shaped or short tetra-shaped or short chain. chain.
Size: 0.5 - 1.0 x 0.5 - 1.0 ~ 0.8 - 1.0 x 1.0 - 1.2 Motility: _ _ Spore: _ _ Gram's stain: + +
Acid-fa8t stain: .. .
C. Physiological properties:
_ ........................ , ~ Strain B-0667 Strain B-0668 .. .
Growth temperature: 45C _ 37C + +
30~C ~ +
; 26~C + +
. 10C + +
5C i or (~) + or ~+) Halotolerance: NaCl 10~ + ~
5.0~ + ~
1.0% ~ +
0% + _ OF-test: fermentative fermentative:
Behavior in oxygen: facultative anaerobic facultative anaerobic Nitrate reduction: _ _ Indole formation: _ _ Hydrogen sulfate formation: _ _ i Gelatin hydrolysis:
~'1~''~
,~
~3~
Table continued:
St:rch hydrolysis:
Esculin hydrolysis: +
Acetoin formation: _ MR-test: _ Catalase: _ O~idase: _ Urease (SSR): _ Urease (Christensen): _ Utilization of citric acid (Christensen): _ Acid ormation from sugar:
adonitol: _ L(+)-arabinose: _ cellobiose: +
dulcitol: _ meso-erythritol: _ fructose: +
fucose: _ galactose:
glucose: +
glycerol: _ inositol: _ inulin: _ lactose: +
raltose: +
mannitol: +
mannose: +
melezitose: _ melibiose: _ "7'`
-~ ~ 6 -~3~;~0 _ . . ..
raffinose: _ L(+~-rhamnose: _ salicin: ~) _ L-sorbose: _ _ sorbitol: _ _ starch: _ sucrose: ~
trehalose: + +
xylose: _ _ ¦ tolerance at 60C for 30 min. _ i ~
.
Consulting "Bergey's Manual of Determinative Bacteriol-ogy, 8th Ed., 1974" and "Cowan, S. T. and Steel, K. J., Manual for the Identification of Medical Bacteria, Cambridge Press, 1974", the strains B-0667 and B-0668 having the taxonomical properties hereinabove, especially Gram positive cocci, catalaseand oxidase negative, fermentative a~id formation from glucose, and no gas formation from sugar (glucose), are referred to as belonging to the genus Pediococcus and the genus Streptococcus.
Comparison of these strains with the identification manual of the above references is as follows.
In the table:~ _ positive more than 85%.
- ~ negative more than 85%.
d ~ varies among ~trains or species.
~_ _ _ . .
. strain B-0667 strain B-0668 genus genu~
. ._ _ ~ _ .__. _ . Pediococcus StreDtococcus growth at 45DC _ _ + d tolerance at 60C
for 30 min. _ ~ _ d glycerol 30tacid formation' _ _ _ d arabinose .
(acid formation) _ _ + d halotolerance _ ~NaCl 10~ _ +
. ~............................... ............... ........ .............. ... .... -. .,~
~3~
Hence the strain B-0667 will be referred to as the genus Pedlococcus or Streptococcus. Consulting the above 'IManual for the Identification of Medical Bacteria" and "J. Gen.Microbiol 26, 185-197 (1961)", the taxonomic properties of the strain B-0667 were almost identical with those of Pediococcus urina-equi, how-ever the characteristics described in "Bergey's Manual of Deter-minative Bacteriology, 8th Ed., 1974" were slightly different therefrom. Therefore the strain B-0667 is referred to as the genus Pedioco;ccus and designated as Pediococcus sp. B-0667 The strain B-0668 resembles the genus Streptococcus rather than the genus Pediococcus. Further consulting the "Manual for the Identification of Medical Bacteria", the strain B-0668 resembles Streptococcus faecium var. durans, however, no taxo-_ _ nomic properties were described in the l'Bergey's Manual" and thereby it is impossible to make a detailed comparison. The strain B-0668, therefore, is referred to as Streptococcus sp.
B-0668.
The strains B-0667 and B-0668 were deposited for perma-nent collection in the Institute for Microbial Industry and Technology, Agency of Industrial Science and Technology, M. I. T.
I., Japan, as deposition numbers FERM-P No. 4438 and FERM-P No.
4439, respectively.
In an embodiment of the present invention, the above Pediococcus sp. B-0667, Streptococcus sp. B-0668, Aerococcus viridans IFO-12219 or Aerococcus viridans IFO-12317 are cultured in a conventional medium for enzyme production. Cultivation can be made by conventional liquid culture and submerged aeration culture is preferable for industrial production.
A conventional medium for microorganisms is preferably used. As for the carbon sources, assimilable carbon sources such as glucose, sucrose, lactose, maltose, fructose, molasses, py-ruvic acid or the like are preferably used. Assimilable nitrogen 3~
sources such as peptone, meat extract, yeast extract, casein hydxolysate or the like can be used. Various inorganic salts such as phosphates~ carbonates, sulfates, or salts of magnesium, calcium, potassium, iron, manganese or zinc can be used.
The culturing temperature can be selected within the range for growth of microbial cells and production of pyruvate oxidase, and is preferably from 2S-37C. The culturing time can be altered depending on conditions and is terminated when the pyruvate oxidase production is substantially complete, and usually ranges from 18-48 hours.
Pyruvate oxidase exists in the cells of microorganisms.
To separate pyruvate oxidase from cultured cells, the cultured mass is filtered or centrifuged to collect the cells, and disrupted by treatment with mechanical means or an enzymatic pro-cess such as lysozyme. Further if necessary pyruvate oxidase is solubilized by adding ethylene-diaminetetraacetic acid (EDTA) and a surfactant such as "Triton X-100" (trade mark) or "Adecatol SO-120" (trade mark) to separate the enzyme. The thus-obtained solution of pyruvate oxidase is treated with or without concen-tration, and thereafter the enzyme is precipitated by salting outwith addition of a soluble salt such as ammonium sulfate or sodium chloride. Low molecular weight impurities are removed by dialysis.
Furthermore impurities in the solution of pyruvate oxidase are preferably removed by adsorption chromatography, ion-exchange chromatography or gel-filtration. The enzyme solution thus ob-tained is treated by vacuum concentration and lyophilization to produce powdered pyruvate oxidase. Further purification can be achieved by conventional purification methods for proteins and enzymes such as adsorption chromatography, ion-exchange chroma-tography or gel~filtration.
Pyruvate oxidase produced by the present invention hasthe following physico-chemical properties, in which abbreviations are used as follows.
_ g _ Pediococcus sp. B-0667; abbreviated as B-0667 ____ .
Streptococcus sp. B~0668; abbreviated as B-0668 .
Aerococcus viridans IFO-12219: abbreviated as IFO-12219 _ . .. ..
Aerococcus viridans IFO-12317: abbreviated as IFO-12317 (1) Enzyme action:
The enzyme catalyzes oxida-tive reaction from pyruvic acid, inorganic phosphate and oxygen to form acetylphosphate, carbon dioxide and hydrogen peroxide.
CH3COCOOH ~ HOPO3 + 02-~CH3COOP03 + C02 + H202 (2) Optimum pH:
The effect of pH on pyruvate oxidase activity is measured. Phosphate buffer solutions of pH 6~8 are used for the assay. The results are shown in Fig. 1 in which the optimum pH
is as follows:
B-0667: pH 6.3-7.5 B-0668: pH 7.5-8.5 IFO-12219: pH 7.0-8.0 IFO-12317: pH 6.8~7.5 Slight variations are observed in phosphate concentra-tion and in the kind of metallic ion.
(3) Heat stability:
Heat stability of the enzyme is determined by incuba-ting in 10 mM phosphate buffer (pH 6.5) containing 10 ~M FAD at 0, 40, 50, 60 and 70C for 10 minutes according to the method of enzyme assay. As shown in Fig. 2 the enzymes obtained from B~0667, IFO-12219 and IFO-12317 are slightly activated at 40 C
and denatured over 60C. The enzyme obtained from B-0668 is not activated at 40C and almost denatured over 60C.
(4) pH stability:
To each enzyme solution (0.1) ml is added 0.2 M phos-phate buffer for pH 6-8 (0.9 ml) or 0~2 M of Tris-HCl buffer for pH 7-9 (0.9 ml) each containing 10 ~M FAD, and the solutions were ~ ,.i~l `
~3~0 allowed to stand for 10 minutes at 40C. 20 ~1 of enzyme solu-tion are taken and the enzyme activity is determined. As shown in Fig. 3, the enzyme obtained from B~0667, IFO-12219 and IFO-12317 is most stable at about pH 7 and that of B-0668 is stable at an acidic pH.
To each enzyme solution (0.1) ml is added 0.2 M phos-phate buffer for pH 6-8 (0.9 ml) or 0~2 M of Tris-HCl buffer for pH 7-9 (0.9 ml) each containing 10 ~M FAD, and the solutions were ~ ,.i~l `
~3~0 allowed to stand for 10 minutes at 40C. 20 ~1 of enzyme solu-tion are taken and the enzyme activity is determined. As shown in Fig. 3, the enzyme obtained from B~0667, IFO-12219 and IFO-12317 is most stable at about pH 7 and that of B-0668 is stable at an acidic pH.
(5) Effect of several substances:
1) The effect of several substances on the enzyme activity is examined by adding 5 mM of the substances indicated below instead of MgC12 in the assay system.
Substance added _ Relative activity (%) . . . . _ _ _ _ . _ No addition 25.4 72.0 42O0 50.3 MgC12 100 100 100 100 CaC12 69.4 75.0 83.4 78.7 MnC12 129.1 102.7 116.2 111.0 CoC12 81.3 81.1 85.0 84.0 BaC12 20.6 58.8 23.9 28.8 ZnC12 16.0 38.2 14.9 22.8 As shown hereinabove, the enzyme is inhibited by EDTA
++ ++ ++ ++
and activated by Mg , Ca , Mn and Co 2) Effect of eliminationof the following substances from the assay system on the enzyme activity is shown below. 0.1 M
dimethylglutarate-NaOH buffer is used in case of phosphate eli-mination.
_ . _ _ .. _ ...... .. . . ... ..... .. . _ .
Substance eliminated Relative activity (%) No elimination 100 100 100 100 thiaminepyrophosphate 0 0 0 0 FAD 33.9 100 32.7 41.7 thiaminepyrophosphate and FAD 0 0 0 0 ph_sphate 0 0 0 ~3~0 As a result, the enzyme requires thiaminepyrophosphate and FAD as cofactor and phosphate as substrate.
Further oxygen consumption in the enzvme reaction is measured by an oxygen-electrode, and the oxygen is consumed in proportion to the enzyme activity (formation of hydrogen peroxide).
The results are shown as follows:
Oxygen consumption Reaction product (~ mole/min.) (~ mole/min.) H2O2 acetylphosphate .
10 B-0667 0.042 0.042 0.038 B-0668 0.022 0.0213 0.020 IFO-122190.040 0.038 0.037 IFO-123170.035 0.036 0.034 . . .
Assays are per~ormed as follows:
Oxygen consumption: dissolved oxygen meter (Trade mark;
YSI-dissolved oxygen meter Model-53) Acetyl phosphate: F. Lipmann et al, J. Biol. Chem., 134, 463-464 (1940).
Hydrogen peroxide: a method using N,N-dimethylaniline, 4-aminoantipyrine and horseradish peroxidase As hereinabove explained, the enzyme obtained from the above four strains is referred to as pyruvate oxidase and flavine protein.
The assay method of pyruvate oxidase of the present invention is as follows.
0.5 M potassium pyruvate 0.1 ml 0.5 M phosphate buffer (pH 7.0) 0.2 ml 0.2%, 4~aminoantipyrine 0.1 ml 0.2% N,N~-dimethylaniline 0.2 ml 0.2 M MgC12 50 ~l 30 10 mM thiaminepyrophosphate 20 ~1 peroxidase (45 U/ml) 0.1 ml 1 mM FAD 10 ~1 distilled water 0.22 ml ~,,~,. ..
~3~
The above reaction mixture (1.0 ml) is pxe-incubated at 37 C for 3 minutes. To this solution is added the enzyme solution (20 ~1) and incubated at 37C for 10 minutes. 0.1 M citrate buf-fer (pH 6.0, 2 ml) containing 0.1 M EDTA is added to terminate the reaction. The violet color formed is measured by a colorimetric method at 565 nm.
A unit (1 unit, 1 U) of enzyme activity is defined as the activity which generates 1 ~mole of hydrogen peroxide per minute.
In order to activate the pyruvate oxidase reaction system, FAD, thiaminepyrophosphate and phosphate are added.
Further for activation of the enzyme, an ion-liberating salt which liberates calcium ion, cobalt ion, magnesium ion or man-ganese ion, in the form of chloride is preferably added thereto.
An indicator such as a coloring indicator or a fluorescent indi-cator for hydrogen peroxide is preferably selected.
The amount and ratio of components in the enzyme reac-tion system can be selected for substantial enzyme reaction and will be varied according to the amount of pyruvate, temperature ar~d time of the enzyme reaction. For example, 1-20 U of pyruvate oxidase, 0.1-20 n moles of FAD, 0.05-0.5 ~ mole of thiaminepyro-phosphate, 1-10 ~ moles of inorganic phosphate and 0.05-10 ~moles of ion liberating salt p~r test is preferably used. Pyruvate oxidase can be in a microcapsulated form or in an immobilized form of covalent linkage with an organic or inorganic carrier or adsorbed on a carrier. The molar ratio of indicator for hydrogen peroxide is at least an equimolar or excess amount of generated hydrogen peroxide. In the case of the peroxidase, o.5-20 U per test is preferably used. These components of the enzymatic reac-tion mixture are preferably used by dissol~ing in the buffer ata suitably ad~usted pH.
~3~
The thus prepared enzymatic xeaction system is applied for analysis of pyruvic acid. Any samples which contain pyru;
vate can be analysed. For example, pyruvic acid itself, pyruvic acid in serum or urine and pyruvic acid forming enzyme reaction systems such as lactic acid and lactate dehydrogenase (LDH)~ ADP
and pyruvate kinase, and glycerol, glycerol kinase and pyruvate kinase can be mentioned. Further detailed examples of the enzy-matic reactions which form pyruvic acid and which can be assayed as are follows:
(1) Assay of lactic acid or LDH activity:
lactate LDH -~ pyruvate + NADH2 (2) Assay of ADP or pyruvate kinase (PK) activity:
ADP ~ phosphoenolpyruvate > ATP + pyruvate (3) Assay of glutamate-pyruvate-transaminase (GPT) activity or ~-ketoglutarate:
alanine + ~-ketoglutarate GPT >pyruvate + glutamate (4) Assay of glutamate-oxaloacetate-transaminase (GOT) activity:
aspartate + ~-ketoglutarate OT ~ oxaloacetate +
glutamate oxaloacetate decarboxylase +
oxaloacetate ~ pyruvate (5) Assay of glycerol or glycerophospho kinase (GK) activity:
glycerol + ATP GK -~ glycerol 3-phosphate + ADP
ADP + phosphoenolpyruvate K _~ pyruvate + ADP
1) The effect of several substances on the enzyme activity is examined by adding 5 mM of the substances indicated below instead of MgC12 in the assay system.
Substance added _ Relative activity (%) . . . . _ _ _ _ . _ No addition 25.4 72.0 42O0 50.3 MgC12 100 100 100 100 CaC12 69.4 75.0 83.4 78.7 MnC12 129.1 102.7 116.2 111.0 CoC12 81.3 81.1 85.0 84.0 BaC12 20.6 58.8 23.9 28.8 ZnC12 16.0 38.2 14.9 22.8 As shown hereinabove, the enzyme is inhibited by EDTA
++ ++ ++ ++
and activated by Mg , Ca , Mn and Co 2) Effect of eliminationof the following substances from the assay system on the enzyme activity is shown below. 0.1 M
dimethylglutarate-NaOH buffer is used in case of phosphate eli-mination.
_ . _ _ .. _ ...... .. . . ... ..... .. . _ .
Substance eliminated Relative activity (%) No elimination 100 100 100 100 thiaminepyrophosphate 0 0 0 0 FAD 33.9 100 32.7 41.7 thiaminepyrophosphate and FAD 0 0 0 0 ph_sphate 0 0 0 ~3~0 As a result, the enzyme requires thiaminepyrophosphate and FAD as cofactor and phosphate as substrate.
Further oxygen consumption in the enzvme reaction is measured by an oxygen-electrode, and the oxygen is consumed in proportion to the enzyme activity (formation of hydrogen peroxide).
The results are shown as follows:
Oxygen consumption Reaction product (~ mole/min.) (~ mole/min.) H2O2 acetylphosphate .
10 B-0667 0.042 0.042 0.038 B-0668 0.022 0.0213 0.020 IFO-122190.040 0.038 0.037 IFO-123170.035 0.036 0.034 . . .
Assays are per~ormed as follows:
Oxygen consumption: dissolved oxygen meter (Trade mark;
YSI-dissolved oxygen meter Model-53) Acetyl phosphate: F. Lipmann et al, J. Biol. Chem., 134, 463-464 (1940).
Hydrogen peroxide: a method using N,N-dimethylaniline, 4-aminoantipyrine and horseradish peroxidase As hereinabove explained, the enzyme obtained from the above four strains is referred to as pyruvate oxidase and flavine protein.
The assay method of pyruvate oxidase of the present invention is as follows.
0.5 M potassium pyruvate 0.1 ml 0.5 M phosphate buffer (pH 7.0) 0.2 ml 0.2%, 4~aminoantipyrine 0.1 ml 0.2% N,N~-dimethylaniline 0.2 ml 0.2 M MgC12 50 ~l 30 10 mM thiaminepyrophosphate 20 ~1 peroxidase (45 U/ml) 0.1 ml 1 mM FAD 10 ~1 distilled water 0.22 ml ~,,~,. ..
~3~
The above reaction mixture (1.0 ml) is pxe-incubated at 37 C for 3 minutes. To this solution is added the enzyme solution (20 ~1) and incubated at 37C for 10 minutes. 0.1 M citrate buf-fer (pH 6.0, 2 ml) containing 0.1 M EDTA is added to terminate the reaction. The violet color formed is measured by a colorimetric method at 565 nm.
A unit (1 unit, 1 U) of enzyme activity is defined as the activity which generates 1 ~mole of hydrogen peroxide per minute.
In order to activate the pyruvate oxidase reaction system, FAD, thiaminepyrophosphate and phosphate are added.
Further for activation of the enzyme, an ion-liberating salt which liberates calcium ion, cobalt ion, magnesium ion or man-ganese ion, in the form of chloride is preferably added thereto.
An indicator such as a coloring indicator or a fluorescent indi-cator for hydrogen peroxide is preferably selected.
The amount and ratio of components in the enzyme reac-tion system can be selected for substantial enzyme reaction and will be varied according to the amount of pyruvate, temperature ar~d time of the enzyme reaction. For example, 1-20 U of pyruvate oxidase, 0.1-20 n moles of FAD, 0.05-0.5 ~ mole of thiaminepyro-phosphate, 1-10 ~ moles of inorganic phosphate and 0.05-10 ~moles of ion liberating salt p~r test is preferably used. Pyruvate oxidase can be in a microcapsulated form or in an immobilized form of covalent linkage with an organic or inorganic carrier or adsorbed on a carrier. The molar ratio of indicator for hydrogen peroxide is at least an equimolar or excess amount of generated hydrogen peroxide. In the case of the peroxidase, o.5-20 U per test is preferably used. These components of the enzymatic reac-tion mixture are preferably used by dissol~ing in the buffer ata suitably ad~usted pH.
~3~
The thus prepared enzymatic xeaction system is applied for analysis of pyruvic acid. Any samples which contain pyru;
vate can be analysed. For example, pyruvic acid itself, pyruvic acid in serum or urine and pyruvic acid forming enzyme reaction systems such as lactic acid and lactate dehydrogenase (LDH)~ ADP
and pyruvate kinase, and glycerol, glycerol kinase and pyruvate kinase can be mentioned. Further detailed examples of the enzy-matic reactions which form pyruvic acid and which can be assayed as are follows:
(1) Assay of lactic acid or LDH activity:
lactate LDH -~ pyruvate + NADH2 (2) Assay of ADP or pyruvate kinase (PK) activity:
ADP ~ phosphoenolpyruvate > ATP + pyruvate (3) Assay of glutamate-pyruvate-transaminase (GPT) activity or ~-ketoglutarate:
alanine + ~-ketoglutarate GPT >pyruvate + glutamate (4) Assay of glutamate-oxaloacetate-transaminase (GOT) activity:
aspartate + ~-ketoglutarate OT ~ oxaloacetate +
glutamate oxaloacetate decarboxylase +
oxaloacetate ~ pyruvate (5) Assay of glycerol or glycerophospho kinase (GK) activity:
glycerol + ATP GK -~ glycerol 3-phosphate + ADP
ADP + phosphoenolpyruvate K _~ pyruvate + ADP
(6) Assay o~ triglyceride:
t i 1 eride lipase or lipoprotelnlipase 3 glycerol 3-phosphate + ADP
ADP + phosphoenolpyruvate ~ pyruvate+ ATP
t i 1 eride lipase or lipoprotelnlipase 3 glycerol 3-phosphate + ADP
ADP + phosphoenolpyruvate ~ pyruvate+ ATP
(7) Assay of creatinine or creatinine phosphokinase (CPK):
creatinine creatininase ~ creatine creatine + ATP ~ creatine phosphate -~ ADP
ADP + phosphoenolpyruvate > pyruvate + ATP
~3~0
creatinine creatininase ~ creatine creatine + ATP ~ creatine phosphate -~ ADP
ADP + phosphoenolpyruvate > pyruvate + ATP
~3~0
(8) Assay of myokinase:
ATP + AMP myOkinase > 2 ADP
ADP + phosphoenolpyruvate PK ~ pyruvate + ATP
ATP + AMP myOkinase > 2 ADP
ADP + phosphoenolpyruvate PK ~ pyruvate + ATP
(9) Assay of fatty acid or thiokinase activity:
fatty acid + CoA ATP thiokinase ~ acyl Coa + AMP + PPi AMP + ATP myokina9e ~ 2 ADP
ADP + phosphoenolypyruvate PK ~ pyruvate + ATP
These enzyme reactions are given only for illustration and thesepyruvate forming reactions can be found with the com-bination of enzyme and its substrate, for example in biologicalsamples. As exemplified hereinabove, the assay can be applied not only for the assay of pyruvate but also for the assay of enzymes, enzyme activity or substrates.
The assay is performed by incubation with the sample and reagent mixture. The reagent mixture is preferably a kit of necessary reagents. For assaying, the consumed component or gen-erated component is measured. Measuring the amount of oxygen consumption by a dissolved oxygen meter is preferable for the assay method. In this case no indicator for hydrogen peroxide is necessary. As for the assaying of a generated component, the measurement of the amount of hydrogen peroxide is preferable, for example by using a hydrogen peroxide electrode meter such as a YSI~oxidase meter or by colorimetric or fluorometric assay with an indicator for hydrogen peroxide. The assay is preferably carried out for a period of 10-60 minutes at 20-40C, preferably at 35-37C.
The indicator for hydrogen peroxide is a combination of one or more chromogens or fluorescers, which is effected by coupling with hydrogen peroxide. Examples of such indicators are a combination of a tetravalent titanium compound and xylenol orange which couples with hydrogen peroxide to form a stable red ~i~ color, or combinations of phenol or N,N-dimethylaniline or homo-vanillic acid~ 4-aminoantipyrine and peroxid~se for measuring color or fluorescence. 4~aminoantipyrine can be replaced by 4~aminophenazone. A combination of 2,6-dichlorophenol, indophenol and peroxidase and of guaiacol and peroxidase can also be used.
The indicator can be previously prepared as a solution. A color-imetric or fluorometric assay is performed by measuring the ab-sorption at a suitable wave length such as 565 nm.
The amount of pyruvic acid can be measured by calculating from a corresponding standard curve of consumed oxygen or gener-ated hydrogen peroxide.
Phosphate as a oonsumed oomponent or aoetylphosphate as a generated ccmponent can also be assayed by a conventional method.
As hereinabove explained, a kit for analysis, especially diagnostic analysis, cMmprising pyruvate oxidase and its use for various assay methods are provided. More particularly as illustrated hereinbefore, diagnostic analyses such as the analysis of pyruvate in a pyruv~te con~;n;ng reagent or in serum or urine, the assay of enzyme activity of LDH, pyruvate kinase, GPT, GOT, glyoerol kinase, lipase, lipoprotein lipase, creatinine, phospho-kinase, myokinase or thiokinase, and the analysis of biological components such as lactate, ADP, glycerol, triglyceride, creatinine or fatty acid can advantageously be made by the kit and method of the present invention.
The follcwing examples illustrate the embodiments of the present invention but are not to be construed as limiting the invention.
Example 1.
A medium (each 100 ml, pH 7) comprising glucose (1%), peptone (1%), yeast extract (0.5%), NaCl (0.2%), KH2PO4 (0.1%), K2HPO4 (0.1~), MgSO4 (0.05%) and CaCO3 (0.3%) in a 500 ml Erlenmeyer flask was sterilized at 120C for 20 minutes. To each medium was inoculated a strain of Pediococcus sp. B-0667 FERM-P
No. 4438, Streptococcus sp. B-0668 FERM-P No. 4439, Aerococcus viridans IFO-12219 or Aerococcus viridans IFO-12317, respectively and the media were shake-cultured at 30C for 24 hours, at 300 ~3~0 r.p.m. Thereafter cultured cells centrifu~ally collected were washed with 10 mM phosphate buffer (pH 6.5) and again centrifuged to collect bacterial cells. The thus obtained cells were sus-pended in the 10 mM phosphate bu~fer (10 ml~ pH 7.0) containing 0.02% lysozyme and 0.1% "Txiton X~100" and incubated at 37C for 60 minutes. The supernatant obtained centrifugally which contains pyruvate oxidase was collected. The enzyme activity of the super-natant is shown in the following table.
Strain Enzyme activity (U/ml) B-0667 0.60 B-0668 0.38 IFO-12219 0.52 IFO-12317 0.46 Example 2.
A medium (20 1.) consisting of the same components as described in Example 1 in a 30 1. Jar-fermenter was sterilized by steam. Cultured broth (200 ml) of Pediococcus sp. B-0667 FERM-P No. 4438, cultured in the same way as in Example 1 was transferred thereto, and cultured at 30C for 24 hours. The bacterial cells centrigually collected (about 100 g) were sus-pended in the lysozyme solution (0.2 mg/ml, 4 1.) there was further added "Triton X-100" (trade mark, 4 g) EDTA t3 g3 and 1 M phosphate buffer (pH 6.5, 40 ml) thereto and the mixture was stirred at 37C for 60 minutes. To the supernatant obtained centrifugally was added ammonium sulfate and the precipitate at 0.54-0.73 saturation was collected by centrifuge. The precipi-tate was dissol~ed in 10 mM phosphate buffer (pH 6.5, 1000 ml) t5160 U, recoYery; 86~), then cold acetone (0.65 ~olume) was added thereto and the impure precipiate was separated. Further acetone (0.3 volume) was added and the precipitate, which was collected by centri~u~er was dissolved in 10 mM phosphate buffer (pH 6.5~ 70 ml) (~750 Ur reco~ery 7~.2~).
- 17 ~
~3~0 To the soluti~n was, added a~monium sulfate and the pre-cipitate at 0.54~0.70 saturation was collected centrifugally.
After dissolving the precipitate in 10 mM phosphate buffer (pH 6.5), the solution was charged on a column of "Sephadex G-25" (trade mark) (6.0 X 70 cm) and the fraction showing the absorbency at 280 nm was collected. The active frac-tions were pooled and freeze dried to obtain a powder of pyru-vate oxidase ('394a U, 758 mg, recovery 65.7%) Example 3.
A kit for pyruvate analysis (for oxygen electrode):
pyruvate oxidase obtained in Example 2 (the same as in the following examples) 300 U
FAD 0.5 ~mole thiamine pyrophosphate 10 ~moles MnC12 25 ~moles 0.2 M phosphate buffer (pH 7.5) 1.0 ml sucrose 0.5 g 0.2 M dimethylglutarate-NaOH buffer (pH 7.5) 5 ml The above mixture is lyophilized to prepare the kit for assay of pyruvic acid (for oxygen electrode measurement, 50 tests).
Example 4 A kit for pyruvate analysis (for colorimetric assay):
Reagent (I) pyruvate oxidase 200 U
FAD 0.5 ~mole thiamine pyrophosphate 10 ~moles 0.2 M phosphate buffer (pH 7.5) 1.0 ml sucrose 0.5 g 0.2 M dimethylglutarate-NaOH buffer (pH 7.5) 5 ml peroxidase (100 U/mg, horseradish) 2.5 mg 0.3~ 4-aminoantipyrine 5 ml ~f~3 3 '~ .
~i~, ,~
~3~
The above mixture is lyophilized to prepare the reagent (I) of the kit for pyruvate analysis (for colorimetry, 50 tests).
Additional reagent (II) consisting of 0.2% aqueous N,N~dimethylaniline containing 25 ~moles MnC12 (50 ml) and a stop reagent (III) consisting of 0.1 M citrate buffer (pH 6.0, 100 ml) containing 0.1 M EDTA were attached.
Example 5.
, _ . . _ .
The kit illustrated in Example 3 was dissolved in dis-tilled water (50 ml) and an aliquot solution (1.0 ml) thereof was put in reaction vessels~ Thereto were added 5.0 mM pyruvate solution (each 0-100 ~1), or human serum 50 ~1 and 5.0 mM pyru-vate solution (each additionally 0--100 ~1), and incubated at 37 C, then the oxygen consumption was measured by a Garvanic oxy-gen electrode. The results are shown in Fig. 4.
Further, the kit shown in Example 3 was dissolved in distilled water (25 ml) and an aliquot solution tO.5 ml) thereof was put in reaction vessels, then incubated with the addition of an aqueous solution (0.5 ml) containing human serum ~0-0.5 ml) at 37 C. In Fig. 5 there is shown the result of assay of oxygen consumption measured by a Garvanic oxygen electrode.
As shown in ~ig. 4 and 5 good linear relations were observed.
Example 6.
The lyophilized reagent (I) prepared in Example 4 was dissolved by addition of reagent (II) (50 ml), and each aliquot solution (1 ml) in the small test tubes were incubated at 37 C.
Thereto was added 5 mM potassium pyruvate solution (each 0-50 ~1), or human serum (50 ~1) added with 5 mM potassium pyruvate solution (each 0-50 ~1), and incubated at 37C for 10 minutes. A stop solu-tion (2 ml~ was added thereto and the absorbency at 565 nm was measured. As sh~wn in Fig. 6, good linear relations and quanti-tative results were observed in the above assays and also in the i~,,~ .
case, this result was coincided with the calibration curve by 22 ( .5 mM H2O2, 0 50 ~1.).
Further aliquot samples of human serum (0-0.5 ml) were put into small test tubes and adjusted to 0.5 ml hy adding dis-tilled water. Each solution (1.0 ml) of reagent (I) prepared with adding reagent (II) in Example 4 was added thereto, and in-cubated at 37C for 10 minutes. The reaction was terminated by adding stop reagent (IIIl (1.5 ml) and colorimetrically assayed at 565 nm. As shown in Fig. 7, a good quantitative result was obtained.
Example 7.
.
Reaction mixture:
0.2 M dimethylglutarate~NaOH buffer (ph 7.5) 0.2 ml
fatty acid + CoA ATP thiokinase ~ acyl Coa + AMP + PPi AMP + ATP myokina9e ~ 2 ADP
ADP + phosphoenolypyruvate PK ~ pyruvate + ATP
These enzyme reactions are given only for illustration and thesepyruvate forming reactions can be found with the com-bination of enzyme and its substrate, for example in biologicalsamples. As exemplified hereinabove, the assay can be applied not only for the assay of pyruvate but also for the assay of enzymes, enzyme activity or substrates.
The assay is performed by incubation with the sample and reagent mixture. The reagent mixture is preferably a kit of necessary reagents. For assaying, the consumed component or gen-erated component is measured. Measuring the amount of oxygen consumption by a dissolved oxygen meter is preferable for the assay method. In this case no indicator for hydrogen peroxide is necessary. As for the assaying of a generated component, the measurement of the amount of hydrogen peroxide is preferable, for example by using a hydrogen peroxide electrode meter such as a YSI~oxidase meter or by colorimetric or fluorometric assay with an indicator for hydrogen peroxide. The assay is preferably carried out for a period of 10-60 minutes at 20-40C, preferably at 35-37C.
The indicator for hydrogen peroxide is a combination of one or more chromogens or fluorescers, which is effected by coupling with hydrogen peroxide. Examples of such indicators are a combination of a tetravalent titanium compound and xylenol orange which couples with hydrogen peroxide to form a stable red ~i~ color, or combinations of phenol or N,N-dimethylaniline or homo-vanillic acid~ 4-aminoantipyrine and peroxid~se for measuring color or fluorescence. 4~aminoantipyrine can be replaced by 4~aminophenazone. A combination of 2,6-dichlorophenol, indophenol and peroxidase and of guaiacol and peroxidase can also be used.
The indicator can be previously prepared as a solution. A color-imetric or fluorometric assay is performed by measuring the ab-sorption at a suitable wave length such as 565 nm.
The amount of pyruvic acid can be measured by calculating from a corresponding standard curve of consumed oxygen or gener-ated hydrogen peroxide.
Phosphate as a oonsumed oomponent or aoetylphosphate as a generated ccmponent can also be assayed by a conventional method.
As hereinabove explained, a kit for analysis, especially diagnostic analysis, cMmprising pyruvate oxidase and its use for various assay methods are provided. More particularly as illustrated hereinbefore, diagnostic analyses such as the analysis of pyruvate in a pyruv~te con~;n;ng reagent or in serum or urine, the assay of enzyme activity of LDH, pyruvate kinase, GPT, GOT, glyoerol kinase, lipase, lipoprotein lipase, creatinine, phospho-kinase, myokinase or thiokinase, and the analysis of biological components such as lactate, ADP, glycerol, triglyceride, creatinine or fatty acid can advantageously be made by the kit and method of the present invention.
The follcwing examples illustrate the embodiments of the present invention but are not to be construed as limiting the invention.
Example 1.
A medium (each 100 ml, pH 7) comprising glucose (1%), peptone (1%), yeast extract (0.5%), NaCl (0.2%), KH2PO4 (0.1%), K2HPO4 (0.1~), MgSO4 (0.05%) and CaCO3 (0.3%) in a 500 ml Erlenmeyer flask was sterilized at 120C for 20 minutes. To each medium was inoculated a strain of Pediococcus sp. B-0667 FERM-P
No. 4438, Streptococcus sp. B-0668 FERM-P No. 4439, Aerococcus viridans IFO-12219 or Aerococcus viridans IFO-12317, respectively and the media were shake-cultured at 30C for 24 hours, at 300 ~3~0 r.p.m. Thereafter cultured cells centrifu~ally collected were washed with 10 mM phosphate buffer (pH 6.5) and again centrifuged to collect bacterial cells. The thus obtained cells were sus-pended in the 10 mM phosphate bu~fer (10 ml~ pH 7.0) containing 0.02% lysozyme and 0.1% "Txiton X~100" and incubated at 37C for 60 minutes. The supernatant obtained centrifugally which contains pyruvate oxidase was collected. The enzyme activity of the super-natant is shown in the following table.
Strain Enzyme activity (U/ml) B-0667 0.60 B-0668 0.38 IFO-12219 0.52 IFO-12317 0.46 Example 2.
A medium (20 1.) consisting of the same components as described in Example 1 in a 30 1. Jar-fermenter was sterilized by steam. Cultured broth (200 ml) of Pediococcus sp. B-0667 FERM-P No. 4438, cultured in the same way as in Example 1 was transferred thereto, and cultured at 30C for 24 hours. The bacterial cells centrigually collected (about 100 g) were sus-pended in the lysozyme solution (0.2 mg/ml, 4 1.) there was further added "Triton X-100" (trade mark, 4 g) EDTA t3 g3 and 1 M phosphate buffer (pH 6.5, 40 ml) thereto and the mixture was stirred at 37C for 60 minutes. To the supernatant obtained centrifugally was added ammonium sulfate and the precipitate at 0.54-0.73 saturation was collected by centrifuge. The precipi-tate was dissol~ed in 10 mM phosphate buffer (pH 6.5, 1000 ml) t5160 U, recoYery; 86~), then cold acetone (0.65 ~olume) was added thereto and the impure precipiate was separated. Further acetone (0.3 volume) was added and the precipitate, which was collected by centri~u~er was dissolved in 10 mM phosphate buffer (pH 6.5~ 70 ml) (~750 Ur reco~ery 7~.2~).
- 17 ~
~3~0 To the soluti~n was, added a~monium sulfate and the pre-cipitate at 0.54~0.70 saturation was collected centrifugally.
After dissolving the precipitate in 10 mM phosphate buffer (pH 6.5), the solution was charged on a column of "Sephadex G-25" (trade mark) (6.0 X 70 cm) and the fraction showing the absorbency at 280 nm was collected. The active frac-tions were pooled and freeze dried to obtain a powder of pyru-vate oxidase ('394a U, 758 mg, recovery 65.7%) Example 3.
A kit for pyruvate analysis (for oxygen electrode):
pyruvate oxidase obtained in Example 2 (the same as in the following examples) 300 U
FAD 0.5 ~mole thiamine pyrophosphate 10 ~moles MnC12 25 ~moles 0.2 M phosphate buffer (pH 7.5) 1.0 ml sucrose 0.5 g 0.2 M dimethylglutarate-NaOH buffer (pH 7.5) 5 ml The above mixture is lyophilized to prepare the kit for assay of pyruvic acid (for oxygen electrode measurement, 50 tests).
Example 4 A kit for pyruvate analysis (for colorimetric assay):
Reagent (I) pyruvate oxidase 200 U
FAD 0.5 ~mole thiamine pyrophosphate 10 ~moles 0.2 M phosphate buffer (pH 7.5) 1.0 ml sucrose 0.5 g 0.2 M dimethylglutarate-NaOH buffer (pH 7.5) 5 ml peroxidase (100 U/mg, horseradish) 2.5 mg 0.3~ 4-aminoantipyrine 5 ml ~f~3 3 '~ .
~i~, ,~
~3~
The above mixture is lyophilized to prepare the reagent (I) of the kit for pyruvate analysis (for colorimetry, 50 tests).
Additional reagent (II) consisting of 0.2% aqueous N,N~dimethylaniline containing 25 ~moles MnC12 (50 ml) and a stop reagent (III) consisting of 0.1 M citrate buffer (pH 6.0, 100 ml) containing 0.1 M EDTA were attached.
Example 5.
, _ . . _ .
The kit illustrated in Example 3 was dissolved in dis-tilled water (50 ml) and an aliquot solution (1.0 ml) thereof was put in reaction vessels~ Thereto were added 5.0 mM pyruvate solution (each 0-100 ~1), or human serum 50 ~1 and 5.0 mM pyru-vate solution (each additionally 0--100 ~1), and incubated at 37 C, then the oxygen consumption was measured by a Garvanic oxy-gen electrode. The results are shown in Fig. 4.
Further, the kit shown in Example 3 was dissolved in distilled water (25 ml) and an aliquot solution tO.5 ml) thereof was put in reaction vessels, then incubated with the addition of an aqueous solution (0.5 ml) containing human serum ~0-0.5 ml) at 37 C. In Fig. 5 there is shown the result of assay of oxygen consumption measured by a Garvanic oxygen electrode.
As shown in ~ig. 4 and 5 good linear relations were observed.
Example 6.
The lyophilized reagent (I) prepared in Example 4 was dissolved by addition of reagent (II) (50 ml), and each aliquot solution (1 ml) in the small test tubes were incubated at 37 C.
Thereto was added 5 mM potassium pyruvate solution (each 0-50 ~1), or human serum (50 ~1) added with 5 mM potassium pyruvate solution (each 0-50 ~1), and incubated at 37C for 10 minutes. A stop solu-tion (2 ml~ was added thereto and the absorbency at 565 nm was measured. As sh~wn in Fig. 6, good linear relations and quanti-tative results were observed in the above assays and also in the i~,,~ .
case, this result was coincided with the calibration curve by 22 ( .5 mM H2O2, 0 50 ~1.).
Further aliquot samples of human serum (0-0.5 ml) were put into small test tubes and adjusted to 0.5 ml hy adding dis-tilled water. Each solution (1.0 ml) of reagent (I) prepared with adding reagent (II) in Example 4 was added thereto, and in-cubated at 37C for 10 minutes. The reaction was terminated by adding stop reagent (IIIl (1.5 ml) and colorimetrically assayed at 565 nm. As shown in Fig. 7, a good quantitative result was obtained.
Example 7.
.
Reaction mixture:
0.2 M dimethylglutarate~NaOH buffer (ph 7.5) 0.2 ml
10 mM MnC12 50 ~1 0.2% N, N-dimethylaniline 0.2 ml 0.3~ 4-aminoantipyrine 0.1 ml peroxidase ~45 U/ml) 0.1 ml 10 mM ~hiamine pyrophosphate 20 ~1 0.2 M phosphate buffer (pH 7.5) 25 ~1 20 mM phosphoenolpyruvate 0.1 ml pyruvate kinase (4000 U/ml) 5 ~1 5 mM ADP 0-50 ~
The above reaction mixture was adjusted to 1.0 ml by adding distilled water, pre-incubated at 37C, then a solution of pyruvate oxidase (200 U/ml, 20 ~1) was added thereto, and incu-bated at 37C for 10 minutes. After stopping the reaction with addition of 0.1 M EDTA in 0.1 M citrate buffer (pH 6.0, 2.0 ml), the absorbency at 565 nm was measured. As shown in Fig. 8, good quantitative results of ADP assay were observed by assaying hydro-gen peroxide generated from the reaction mixture of ADP, pyruvate kinase, phosphoenol-pyruvate and others.
Also as shown in Fig. 8 good linearity was observed when 2.5 mM hydrogen peroxide were used instead of 5 mM ADP.
Example 8.
.
Triglyceride assay kit:
Reagent (I):
0.2 M dimethylglutarate-NaOH buffer (pH 7.5) 10 ml 0.3% ~-aminoantipyrine 5 ml peroxidase (100 U/mg) 2.5 mg thiamine pyrophosphate 10 ~moles 0.2 M phosphate buffer (pH 7.5) 1.25 ml phosphoenolpyruvate 100 ~moles pyruvate kinase (4000 U/ml) 0.1 ml pyruvate oxidase (200 U/ml) 2 ml lipoprotein lipase (3000 U/ml) 0.5 ml glycerol phosphokinase (300 U/ml)1.0 ml ATP 100 ~moles The above reagent was lyophilized.
Rea~ent (II):
25 ~ moles of MnCl2 in 0.2% dimethylaniline 50 ml Reagent (III): (stopper solution) 0.1 M EDTA in 0.1 M citrate buffer (pH 6.0) 100 ml _ample 9.
Reagent (I) in Example 8 was dissolved by reagent (II) and each aliquot solution (1.0 mll thereof was put in the test tubes.
Each ali~lot sample (0-50 ~l) of human serum containing 1.02 ~ mole/ml of triglyceride, 5 mM glycerol solution, 4.2 mM
triolein in 0.1~ "Triton X-100" solution or 2.5 mM hydrogen per-oxide solution, respectively~ was added thereto and incubated at 37 C for 10 minutes. As shown in Fig. 9 good linearities were observed.
~i/, o Example lQ.
A kit for assay of serum transaminase; (for 100 tests);
(1) A kit for GPT assay: (for 100 tests);
Reagent (I): lyophilized rea~ent consisting of the following:
pyruvate oxidase 400 U
FAD 500 n moles thiamine pyrophosphate 15~.~ moles L-alanine 20 m moles ~-keto~lutarate 1 m mole sucrose 1 g 4-aminoantipyrine 150 ~ moles peroxidase 450 U
0.2 M phosphate buffer (ph 7.5) 2.5 ml 0.2 M dimethylglutarate-NaOH buffer (ph 7.5) 30 ml Reagent (II): ~100 ml are used for Reagent (I)~;
42 ~ moles MnC12 in 0.2% dimethylaniline solution 210 ml Reagent (III): (st.opper solution); r2oo ml for Reagent (I), 2.0 ml per one testJ;
0.1 M EDTA in 0.2 M citrate buffer (ph 5.0) 420 ml 0 (2) A kit for GOT assay: (for 100 tests);
Reagent (I): Lyophilized reagent consisting of the following;
pyru~ate oxidase 400 U -FAD 500 n moles thiamine pyrophosphate 150 ~ moles L-aspartic acid 20 m moles ~- ketoglutarate 1 m mole oxaloacetate decarboxylase 200 U
sucrose 1 g 4-aminoantipyrine 150 ~ moles peroxidase 450 U
0.2 M phosphate buffer (ph 7.5~ 2.5 ml ~3~0 0.2 ~ dimethylglutarate~N~OH buffer (ph 7.5) 30 ml Reagent (II) and Reagent (III):
The same as the above (1).
Example 11.
Reagents (I) prepared in Example 10, (1) (for GPT acti-vity assay) and (2) (for GOT activity assay), were dissolved by adding reagent (II) (100 ml) respectively. Each aliquot amount (1.0 ml) of the solution was separately put into small test tubes and pre-incubated at 37C for 5 minutes Lpre-incubated solution of reagent (I)J . The standard serum solution (20 ~1) (Calbiochem Co., trade mark: "Maxitol", containing GPT 700 K U/ml and GOT
1000 K U~ml) diluted with constant ratio was added thereto and incubated at 37C for 10 minutes. The reaction was stopped by adding stopping reagent (III) (2.0 ml) and the absorbency at 565 nm was measured. As shown in Fig. 10, both enzyme activities have linearity up to an optical density of about 1.0 (enzyme activity: about 750 K U/ml).
Example 12 To each pre-incubated solution of reagent (I) obtained in Example 11 were added 20 ~1 of human serums (45 samples) and incubated at 37 C for 20 minutes. Stopping reagent (III) (2.0 ml) was added thereto and the absorbency at 565 nm was measured.
~lso the same samples of human serums were assayed by LKB method (ultra violet absorption method, GOT assay kit and GPT
assay kit, made in LKB Corp.) and the correlation was plotted with activity of GPT and GOT.
As shown in Fig. 11, the correlation coefficient; r =
0.998 and the regression equation; y - 0.00295 x ~ 0.0032 forGP~
assay were observed.
On GOT assay, the correlation pattern is shown in Fig.
12, in which the correlation coefficient, r ~ 0.966 and the regression equation; y _ 0.00287 x ~ 0.0180 resulted.
~3 ~...,. ~
The above reaction mixture was adjusted to 1.0 ml by adding distilled water, pre-incubated at 37C, then a solution of pyruvate oxidase (200 U/ml, 20 ~1) was added thereto, and incu-bated at 37C for 10 minutes. After stopping the reaction with addition of 0.1 M EDTA in 0.1 M citrate buffer (pH 6.0, 2.0 ml), the absorbency at 565 nm was measured. As shown in Fig. 8, good quantitative results of ADP assay were observed by assaying hydro-gen peroxide generated from the reaction mixture of ADP, pyruvate kinase, phosphoenol-pyruvate and others.
Also as shown in Fig. 8 good linearity was observed when 2.5 mM hydrogen peroxide were used instead of 5 mM ADP.
Example 8.
.
Triglyceride assay kit:
Reagent (I):
0.2 M dimethylglutarate-NaOH buffer (pH 7.5) 10 ml 0.3% ~-aminoantipyrine 5 ml peroxidase (100 U/mg) 2.5 mg thiamine pyrophosphate 10 ~moles 0.2 M phosphate buffer (pH 7.5) 1.25 ml phosphoenolpyruvate 100 ~moles pyruvate kinase (4000 U/ml) 0.1 ml pyruvate oxidase (200 U/ml) 2 ml lipoprotein lipase (3000 U/ml) 0.5 ml glycerol phosphokinase (300 U/ml)1.0 ml ATP 100 ~moles The above reagent was lyophilized.
Rea~ent (II):
25 ~ moles of MnCl2 in 0.2% dimethylaniline 50 ml Reagent (III): (stopper solution) 0.1 M EDTA in 0.1 M citrate buffer (pH 6.0) 100 ml _ample 9.
Reagent (I) in Example 8 was dissolved by reagent (II) and each aliquot solution (1.0 mll thereof was put in the test tubes.
Each ali~lot sample (0-50 ~l) of human serum containing 1.02 ~ mole/ml of triglyceride, 5 mM glycerol solution, 4.2 mM
triolein in 0.1~ "Triton X-100" solution or 2.5 mM hydrogen per-oxide solution, respectively~ was added thereto and incubated at 37 C for 10 minutes. As shown in Fig. 9 good linearities were observed.
~i/, o Example lQ.
A kit for assay of serum transaminase; (for 100 tests);
(1) A kit for GPT assay: (for 100 tests);
Reagent (I): lyophilized rea~ent consisting of the following:
pyruvate oxidase 400 U
FAD 500 n moles thiamine pyrophosphate 15~.~ moles L-alanine 20 m moles ~-keto~lutarate 1 m mole sucrose 1 g 4-aminoantipyrine 150 ~ moles peroxidase 450 U
0.2 M phosphate buffer (ph 7.5) 2.5 ml 0.2 M dimethylglutarate-NaOH buffer (ph 7.5) 30 ml Reagent (II): ~100 ml are used for Reagent (I)~;
42 ~ moles MnC12 in 0.2% dimethylaniline solution 210 ml Reagent (III): (st.opper solution); r2oo ml for Reagent (I), 2.0 ml per one testJ;
0.1 M EDTA in 0.2 M citrate buffer (ph 5.0) 420 ml 0 (2) A kit for GOT assay: (for 100 tests);
Reagent (I): Lyophilized reagent consisting of the following;
pyru~ate oxidase 400 U -FAD 500 n moles thiamine pyrophosphate 150 ~ moles L-aspartic acid 20 m moles ~- ketoglutarate 1 m mole oxaloacetate decarboxylase 200 U
sucrose 1 g 4-aminoantipyrine 150 ~ moles peroxidase 450 U
0.2 M phosphate buffer (ph 7.5~ 2.5 ml ~3~0 0.2 ~ dimethylglutarate~N~OH buffer (ph 7.5) 30 ml Reagent (II) and Reagent (III):
The same as the above (1).
Example 11.
Reagents (I) prepared in Example 10, (1) (for GPT acti-vity assay) and (2) (for GOT activity assay), were dissolved by adding reagent (II) (100 ml) respectively. Each aliquot amount (1.0 ml) of the solution was separately put into small test tubes and pre-incubated at 37C for 5 minutes Lpre-incubated solution of reagent (I)J . The standard serum solution (20 ~1) (Calbiochem Co., trade mark: "Maxitol", containing GPT 700 K U/ml and GOT
1000 K U~ml) diluted with constant ratio was added thereto and incubated at 37C for 10 minutes. The reaction was stopped by adding stopping reagent (III) (2.0 ml) and the absorbency at 565 nm was measured. As shown in Fig. 10, both enzyme activities have linearity up to an optical density of about 1.0 (enzyme activity: about 750 K U/ml).
Example 12 To each pre-incubated solution of reagent (I) obtained in Example 11 were added 20 ~1 of human serums (45 samples) and incubated at 37 C for 20 minutes. Stopping reagent (III) (2.0 ml) was added thereto and the absorbency at 565 nm was measured.
~lso the same samples of human serums were assayed by LKB method (ultra violet absorption method, GOT assay kit and GPT
assay kit, made in LKB Corp.) and the correlation was plotted with activity of GPT and GOT.
As shown in Fig. 11, the correlation coefficient; r =
0.998 and the regression equation; y - 0.00295 x ~ 0.0032 forGP~
assay were observed.
On GOT assay, the correlation pattern is shown in Fig.
12, in which the correlation coefficient, r ~ 0.966 and the regression equation; y _ 0.00287 x ~ 0.0180 resulted.
~3 ~...,. ~
Claims (11)
1. A kit for analysis of Pyruvic Acid comprising a reaction system which contains pyruvate oxidase which catalyses the reaction to generate acetylphosphate, carbon dioxide and hydrogen peroxide from pyruvate, inorganic phosphate and oxygen; thiamine pyrophosphate, phosphate, and a salt which liberates calcium ion, cobalt ion, magnesium ion, or manganese ion.
2. A kit as claimed in Claim 1 which also includes flavine adenine dinucleotide (FAD) and an indicator for hydrogen peroxide.
3. A kit as claimed in Claim 2 wherein the indicator for hydrogen peroxide consists of peroxidase, 4-aminoantipyrine and phenol or N,N-dimethylaniline or homovanillic acid.
4. A kit as claimed in Claim 1 wherein the pyruvate oxidase is an enzyme obtained from a culture of a pyruvate oxi-dase-producing microorganism belonging to the genus selected from the group consisting of Pediococcus, Streptococcus and Aerococcus.
5. A method for analysis of pyruvic acid or of a py-ruvate liberating system, which method comprises treating said sample with a reaction system containing pyruvate oxidase which catalyses the reaction to generate actylphosphate, carbon dioxide and hydrogen peroxide from pyruvate, inorganic phosphate and oxygen; thiamine pyrophosphate, flavine adenine dinucleotide (FAD), phosphate, and a salt which liberates calcium ion, cobalt ion, magnesium ion or manganese ion; and measuring the oxygen which is consumed or the hydrogen peroxide which is generated.
6. A method as claimed in Claim 5 wherein the said pyruvate liberating system is an enzyme reaction system which generates pyruvates.
7. A method as claimed in Claim 5 wherein the reaction system containing pyruvate oxidase also includes an indicator for hydrogen peroxide.
8. A method as claimed in Claim 7 wherein the said indicator for hydrogen peroxide consists of peroxidase, 4-amino-antipyrine, and phenol or N,N-dimethylaniline or homovanillic acid.
9. A method as claimed in Claim 5 wherein the pyruvate oxidase is an enzyme obtained from a culture of a pyruvate oxidase-producing microorganism belonging to the genus selected from the group consisting of Pediococcus, Streptococcus and Aerococcus.
10. A process for manufacture of pyruvate oxidase which comprises culturing a pyruvate oxidase-producing microorganism belonging to the genus Pediococcus, Streptococcus and Aerococcus in a nutrient culture medium and isolating the pyruvate oxidase thus produced from the cultured cells thereof.
11. A process as claimed in Claim 10 wherein the pyru-vate oxidase-producing microorganism is Pediococcus sp. B-0667 FERM-P No. 4438, Streptococcus sp. B-0668 FERM-P No. 4439, Aerococcus viridans IFO-12219 or Aerococcus viridans IFO-12317.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3468778A JPS5840465B2 (en) | 1978-03-25 | 1978-03-25 | Method for producing pyruvate oxidase |
JP53-34687 | 1978-03-25 | ||
JP53-86350 | 1978-07-14 | ||
JP8635078A JPS5915637B2 (en) | 1978-07-14 | 1978-07-14 | Analytical kit and method using pyruvate oxidase |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1143640A true CA1143640A (en) | 1983-03-29 |
Family
ID=26373526
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000324045A Expired CA1143640A (en) | 1978-03-25 | 1979-03-23 | Process for manufacture of pyruvate oxidase and its use for the analysis and kit |
Country Status (8)
Country | Link |
---|---|
US (1) | US4246342A (en) |
CA (1) | CA1143640A (en) |
DE (2) | DE2911481C2 (en) |
DK (1) | DK156253C (en) |
FR (2) | FR2420760B1 (en) |
GB (2) | GB2020018B (en) |
IT (1) | IT1165650B (en) |
SE (1) | SE445928B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4246342A (en) | 1978-03-25 | 1981-01-20 | Toyo Jozo Kabushiki Kaisha | Process for the manufacture of pyruvate oxidase, and analytical method and kit for the use of the same |
DE2950381A1 (en) * | 1979-12-14 | 1981-06-19 | Boehringer Mannheim Gmbh, 6800 Mannheim | METHOD AND REAGENT FOR DETERMINING TRIGLYCERIDES |
US4316954A (en) | 1980-04-18 | 1982-02-23 | Eastman Kodak Company | Assay for neuraminic acids |
JPS57144996A (en) * | 1981-02-27 | 1982-09-07 | Fuji Photo Film Co Ltd | Film for quantitative analysis |
JPS57208998A (en) * | 1981-06-17 | 1982-12-22 | Fuji Photo Film Co Ltd | Multi-layered analytical film for determination of transaminase |
DE3221730A1 (en) * | 1982-06-09 | 1983-12-15 | Boehringer Mannheim Gmbh, 6800 Mannheim | METHOD AND ANALYTICAL AGENTS FOR DETERMINING THE ACTIVITY OF GLUTAMATE-OXALACETATE-TRANSAMINASE |
DE3306719A1 (en) * | 1983-02-25 | 1984-08-30 | Boehringer Mannheim Gmbh, 6800 Mannheim | PYRUVATOXIDASE |
JPS6034181A (en) * | 1983-08-04 | 1985-02-21 | Kyowa Hakko Kogyo Co Ltd | Preparation of neuraminidase |
IT1205338B (en) * | 1983-08-09 | 1989-03-15 | Miles Italiana | COMPOSITION AND METHOD FOR THE ENZYMATIC DETERMINATION OF UREA IN ORGANIC LIQUIDS |
US4812400A (en) * | 1986-07-14 | 1989-03-14 | Steinman Gary D | Process for measuring sodium levels in biological fluids |
US4965194A (en) * | 1986-08-21 | 1990-10-23 | Toyo Boseki Kabushiki Kaisha | Pyruvate oxidase and an analytical method using the same |
JPS63137699A (en) * | 1986-11-28 | 1988-06-09 | Fuji Photo Film Co Ltd | Analytical element for measuring enzymic activity |
DE3886225T2 (en) * | 1987-01-06 | 1994-03-31 | Asahi Chemical Ind | Pyruvate oxidase, its production and use. |
JP3034969B2 (en) * | 1991-03-01 | 2000-04-17 | 旭化成工業株式会社 | Highly sensitive method for determining ammonia, α-amino acids or α-keto acids and composition for highly sensitive determination |
US5462858A (en) * | 1993-12-29 | 1995-10-31 | Eastman Kodak Company | Dry multilayer analytical elements for assaying transaminases |
AU4325900A (en) | 1999-03-17 | 2000-10-04 | Board Of Trustees Of The Leland Stanford Junior University | In vitro macromolecule biosynthesis methods using exogenous amino acids and a novel atp regeneration system |
US7410755B2 (en) * | 2005-02-22 | 2008-08-12 | Discoverx | ADP detection using an enzyme-coupled reaction |
CN101177686B (en) * | 2006-11-10 | 2011-05-18 | 中国科学院上海生命科学研究院 | Acetonic acid oxidase gene, recombinant expression plasmid and transformation strains thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK678474A (en) * | 1974-02-15 | 1975-10-13 | Hoffmann La Roche | |
US4246342A (en) * | 1978-03-25 | 1981-01-20 | Toyo Jozo Kabushiki Kaisha | Process for the manufacture of pyruvate oxidase, and analytical method and kit for the use of the same |
-
1979
- 1979-03-21 US US06/022,442 patent/US4246342A/en not_active Expired - Lifetime
- 1979-03-22 DE DE2911481A patent/DE2911481C2/en not_active Expired
- 1979-03-22 DE DE2954385A patent/DE2954385C2/de not_active Expired
- 1979-03-23 FR FR7907379A patent/FR2420760B1/en not_active Expired
- 1979-03-23 GB GB7910302A patent/GB2020018B/en not_active Expired
- 1979-03-23 CA CA000324045A patent/CA1143640A/en not_active Expired
- 1979-03-23 GB GB8005344A patent/GB2043650B/en not_active Expired
- 1979-03-23 SE SE7902648A patent/SE445928B/en not_active IP Right Cessation
- 1979-03-23 DK DK119679A patent/DK156253C/en not_active IP Right Cessation
- 1979-03-26 IT IT67627/79A patent/IT1165650B/en active
- 1979-11-23 FR FR7928962A patent/FR2436182A1/en active Granted
Also Published As
Publication number | Publication date |
---|---|
FR2420760A1 (en) | 1979-10-19 |
DE2911481A1 (en) | 1979-10-04 |
IT7967627A0 (en) | 1979-03-26 |
FR2436182B1 (en) | 1983-09-09 |
FR2436182A1 (en) | 1980-04-11 |
GB2020018B (en) | 1982-11-10 |
FR2420760B1 (en) | 1985-04-19 |
DE2954385C2 (en) | 1989-10-26 |
US4246342A (en) | 1981-01-20 |
SE7902648L (en) | 1979-09-26 |
SE445928B (en) | 1986-07-28 |
DK156253C (en) | 1989-12-11 |
DE2911481C2 (en) | 1985-01-24 |
GB2020018A (en) | 1979-11-07 |
DK119679A (en) | 1979-09-26 |
IT1165650B (en) | 1987-04-22 |
DK156253B (en) | 1989-07-17 |
GB2043650A (en) | 1980-10-08 |
GB2043650B (en) | 1982-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1143640A (en) | Process for manufacture of pyruvate oxidase and its use for the analysis and kit | |
US4202941A (en) | Glycerol oxidase and process for the production thereof and method for the quantitative determination of glycerol by glycerol oxidase | |
US4135980A (en) | Choline oxidase | |
US4491631A (en) | Assay method for lipid component, assay composition, and process for production of enzyme used therefor | |
US5356790A (en) | Highly sensitive assay method for myo-inositol, composition for practicing same, novel myo-inositol dehydrogenase, and process for producing same | |
CA1130739A (en) | Lactate oxidase, process for manufacture thereof and analytical method and kit for the use of the same | |
US5266463A (en) | Highly sensitive assay method for L-carnitine and composition for practicing same | |
WO1997031103A1 (en) | Method for determining 1,5-anhydroglucitol | |
US4921786A (en) | Novel NAD synthetase, assay method using said novel NAD synthetase and a process for production thereof | |
JPH0284178A (en) | N-acetyl hexosamine dehydrogenase, its production and quantification of n-acethyl glucosamine or n-acethyl galactosamine using same and kit therefor | |
US4965194A (en) | Pyruvate oxidase and an analytical method using the same | |
US4275161A (en) | Process for the manufacture of L-α-glycerophosphate oxidase | |
US4960701A (en) | N-acetylmannosamine dehydrogenase, process for its production, method for quantitatively analyzing N-acetylmannosamine or sialic acid, and kit for the quantitative analysis | |
EP0029765B1 (en) | Creatinine iminohydrolase free from urease activity, methods of preparation and use, and assay compositions and analytical elements containing same | |
KR950012760B1 (en) | Novel nad synthetase | |
JPS6368099A (en) | Analyzing method by using pyruvic acid oxydase and reagent thereof | |
JPS5915637B2 (en) | Analytical kit and method using pyruvate oxidase | |
DK158681B (en) | EQUIPMENT FOR PYRODRUIC ACID ANALYSIS. | |
JPH0661278B2 (en) | Sensitive method for quantitative determination of myo-inositol and composition for quantitative determination | |
SE441931B (en) | Process and agent for determination of pyro-grape acid or pyruvates | |
Laughon | Growth and metabolism of Aquaspirillum gracile | |
JPH08289781A (en) | New n-alkylglycine oxidase, its production, reagent for determining n (epsilon)-carboxymethyllysine and its determination | |
JPS5840465B2 (en) | Method for producing pyruvate oxidase | |
JPS6140400B2 (en) | ||
JPH0677520B2 (en) | Method for measuring pyruvic acid and its reagent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |